Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Satish Garg to Middle Aged

This is a "connection" page, showing publications Satish Garg has written about Middle Aged.

 
Connection Strength
  
 
 
1.212
  
  1. Garg SK, Bailey TS, Castorino K, Christiansen MP, Liljenquist DR, Salazar H, Akturk HK, Gao S, Johnson ML, Beck SE. Accuracy of the 15.5-Day G7 iCGM in Adults with Diabetes. Diabetes Technol Ther. 2025 Jun; 27(6):430-438.
    View in: PubMed
    Score: 0.054
  2. Garg SK, Kaur G, Renner D, Lanning MS, Mason E, Beatson C, Ciesco K, Snell-Bergeon J. Cardiovascular and Renal Biomarkers in Overweight and Obese Adults with Type 1 Diabetes Treated with Tirzepatide for 21 Months. Diabetes Technol Ther. 2025 Mar; 27(3):152-160.
    View in: PubMed
    Score: 0.054
  3. Snell-Bergeon JK, Kaur G, Renner D, Akturk HK, Beatson C, Garg SK. Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes. Diabetes Technol Ther. 2025 Jan; 27(1):1-9.
    View in: PubMed
    Score: 0.053
  4. Garg SK, Hirsch IB, Repetto E, Snell-Bergeon J, Ulmer B, Perkins C, Bergenstal RM. Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: real-world analysis. Diabetes Obes Metab. 2024 Nov; 26(11):5202-5210.
    View in: PubMed
    Score: 0.052
  5. Boeder S, Davies MJ, McGill JB, Pratley R, Girard M, Banks P, Pettus J, Garg S. Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin. Diabetes Technol Ther. 2024 Sep; 26(9):618-625.
    View in: PubMed
    Score: 0.051
  6. Garg SK, Akturk HK, Kaur G, Beatson C, Snell-Bergeon J. Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes. Diabetes Technol Ther. 2024 Jun; 26(6):367-374.
    View in: PubMed
    Score: 0.050
  7. Garg SK, Grunberger G, Weinstock R, Lawson ML, Hirsch IB, DiMeglio LA, Pop-Busui R, Philis-Tsimikas A, Kipnes M, Liljenquist DR, Brazg RL, Kudva YC, Buckingham BA, McGill JB, Carlson AL, Criego AB, Christiansen MP, Kaiserman KB, Griffin KJ, Forlenza GP, Bode BW, Slover RH, Keiter A, Ling C, Marinos B, Cordero TL, Shin J, Lee SW, Rhinehart AS, Vigersky RA. Improved Glycemia with Hybrid Closed-Loop Versus Continuous Subcutaneous Insulin Infusion Therapy: Results from a Randomized Controlled Trial. Diabetes Technol Ther. 2023 01; 25(1):1-12.
    View in: PubMed
    Score: 0.046
  8. Garg SK, Wernicke-Panten K, Wardecki M, Kramer D, Delalande F, Franek E, Sadeharju K, Monchamp T, Mukherjee B, Shah VN. Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1). Diabetes Technol Ther. 2020 02; 22(2):85-95.
    View in: PubMed
    Score: 0.038
  9. Thrasher J, Polsky S, Hovsepian L, Nowotny I, Pierre S, Bois De Fer B, Bhargava A, Mukherjee B, Garg SK. Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial. Diabetes Technol Ther. 2020 09; 22(9):666-673.
    View in: PubMed
    Score: 0.038
  10. Danne T, Pettus J, Giaccari A, Cariou B, Rodbard H, Weinzimer SA, Bonnemaire M, Sawhney S, Stewart J, Wang S, Castro RC, Garg SK. Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes. Diabetes Technol Ther. 2019 09; 21(9):471-477.
    View in: PubMed
    Score: 0.037
  11. Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA, Maahs DM, Tamborlane WV, Bergenstal R, Smith E, Olson BA, Garg SK. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. Diabetes Technol Ther. 2019 02; 21(2):66-72.
    View in: PubMed
    Score: 0.035
  12. Akturk HK, Snell-Bergeon JK, Rewers A, Klaff LJ, Bode BW, Peters AL, Bailey TS, Garg SK. Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study. Diabetes Technol Ther. 2018 10; 20(10):639-647.
    View in: PubMed
    Score: 0.034
  13. Wadwa RP, Laffel LM, Shah VN, Garg SK. Accuracy of a Factory-Calibrated, Real-Time Continuous Glucose Monitoring System During 10 Days of Use in Youth and Adults with Diabetes. Diabetes Technol Ther. 2018 06; 20(6):395-402.
    View in: PubMed
    Score: 0.034
  14. Shah VN, Laffel LM, Wadwa RP, Garg SK. Performance of a Factory-Calibrated Real-Time Continuous Glucose Monitoring System Utilizing an Automated Sensor Applicator. Diabetes Technol Ther. 2018 06; 20(6):428-433.
    View in: PubMed
    Score: 0.034
  15. Home P, Derwahl KM, Ziemen M, Wernicke-Panten K, Pierre S, Kirchhein Y, Garg SK. Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes. Diabetes Technol Ther. 2018 02; 20(2):160-170.
    View in: PubMed
    Score: 0.033
  16. Thrasher J, Surks H, Nowotny I, Pierre S, Rotthaeuser B, Wernicke-Panten K, Garg S. Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump. J Diabetes Sci Technol. 2018 05; 12(3):680-686.
    View in: PubMed
    Score: 0.033
  17. Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher GR, Pozzilli P, Gesty-Palmer D, Lapuerta P, Sim? R, Danne T, McGuire DK, Kushner JA, Peters A, Strumph P. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. N Engl J Med. 2017 12 14; 377(24):2337-2348.
    View in: PubMed
    Score: 0.032
  18. Ji L, Zhang P, Zhu D, Li X, Ji J, Lu J, Guo X, Jia W, Weng J, Wu Y, Yang W, Zou D, Zhou Z, Pan C, Gao Y, Garg SK. Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: Real-life use of basal insulin in China. Diabetes Obes Metab. 2017 06; 19(6):822-830.
    View in: PubMed
    Score: 0.031
  19. Garg SK, Hirsch IB. Self-Monitoring of Blood Glucose. Diabetes Technol Ther. 2017 02; 19(S1):S3-S10.
    View in: PubMed
    Score: 0.031
  20. Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS, Brazg RL, Ilany J, Slover RH, Anderson SM, Bergenstal RM, Grosman B, Roy A, Cordero TL, Shin J, Lee SW, Kaufman FR. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes. Diabetes Technol Ther. 2017 03; 19(3):155-163.
    View in: PubMed
    Score: 0.031
  21. Ji L, Zhang P, Weng J, Lu J, Guo X, Jia W, Yang W, Zou D, Zhou Z, Pan C, Gao Y, Li X, Zhu D, Li Y, Wu Y, Garg SK. Observational Registry of Basal Insulin Treatment (ORBIT) in Patients with Type 2 Diabetes Uncontrolled by Oral Hypoglycemic Agents in China--Study Design and Baseline Characteristics. Diabetes Technol Ther. 2015 Oct; 17(10):735-44.
    View in: PubMed
    Score: 0.027
  22. Garg SK, Admane K, Freemantle N, Odawara M, Pan CY, Misra A, Jarek-Martynowa IR, Abbas-Raza S, Mirasol RC, Perfetti R. Patient-led versus physician-led titration of insulin glargine in patients with uncontrolled type 2 diabetes: a randomized multinational ATLAS study. Endocr Pract. 2015 Feb; 21(2):143-57.
    View in: PubMed
    Score: 0.027
  23. Garg SK, Aurand LA, Rimler MS, Dailey GE. Diabetes duration and the efficacy and safety of insulin glargine versus comparator treatment in patients with type 2 diabetes mellitus. Endocr Pract. 2014 Feb; 20(2):120-8.
    View in: PubMed
    Score: 0.025
  24. Ahmann A, Szeinbach SL, Gill J, Traylor L, Garg SK. Comparing patient preferences and healthcare provider recommendations with the pen versus vial-and-syringe insulin delivery in patients with type 2 diabetes. Diabetes Technol Ther. 2014 Feb; 16(2):76-83.
    View in: PubMed
    Score: 0.025
  25. Garg SK, Moser EG, Bode BW, Klaff LJ, Hiatt WR, Beatson C, Snell-Bergeon JK. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract. 2013 Jan-Feb; 19(1):19-28.
    View in: PubMed
    Score: 0.023
  26. Garg S, Brazg RL, Bailey TS, Buckingham BA, Slover RH, Klonoff DC, Shin J, Welsh JB, Kaufman FR. Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study. Diabetes Technol Ther. 2012 Mar; 14(3):205-9.
    View in: PubMed
    Score: 0.022
  27. Davis SN, Wei W, Garg S. Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting. Endocr Pract. 2011 Nov-Dec; 17(6):845-52.
    View in: PubMed
    Score: 0.021
  28. Garg SK, Voelmle MK, Beatson CR, Miller HA, Crew LB, Freson BJ, Hazenfield RM. Use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injections versus continuous subcutaneous insulin infusion therapy: a prospective 6-month study. Diabetes Care. 2011 Mar; 34(3):574-9.
    View in: PubMed
    Score: 0.020
  29. Rodbard D, Jovanovic L, Garg SK. Responses to continuous glucose monitoring in subjects with type 1 diabetes using continuous subcutaneous insulin infusion or multiple daily injections. Diabetes Technol Ther. 2009 Dec; 11(12):757-65.
    View in: PubMed
    Score: 0.019
  30. Garg SK, Mathieu C, Rais N, Gao H, Tobian JA, Gates JR, Ferguson JA, Webb DM, Berclaz PY. Two-year efficacy and safety of AIR inhaled insulin in patients with type 1 diabetes: An open-label randomized controlled trial. Diabetes Technol Ther. 2009 Sep; 11 Suppl 2:S5-S16.
    View in: PubMed
    Score: 0.018
  31. Garg SK, Kelly WC, Voelmle MK, Ritchie PJ, Gottlieb PA, McFann KK, Ellis SL. Continuous home monitoring of glucose: improved glycemic control with real-life use of continuous glucose sensors in adult subjects with type 1 diabetes. Diabetes Care. 2007 Dec; 30(12):3023-5.
    View in: PubMed
    Score: 0.016
  32. Bailey TS, Zisser HC, Garg SK. Reduction in hemoglobin A1C with real-time continuous glucose monitoring: results from a 12-week observational study. Diabetes Technol Ther. 2007 Jun; 9(3):203-10.
    View in: PubMed
    Score: 0.016
  33. Garg SK, Rosenstock J, Ways K. Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine. Endocr Pract. 2005 Jan-Feb; 11(1):11-7.
    View in: PubMed
    Score: 0.013
  34. Garg SK, Carter JA, Mullen L, Folker AC, Parkes JL, Tideman AM. The clinical performance and ease of use of a blood glucose meter that uses a 10-test disk. Diabetes Technol Ther. 2004 Aug; 6(4):495-502.
    View in: PubMed
    Score: 0.013
  35. Carlson AL, Sherr JL, Shulman DI, Garg SK, Pop-Busui R, Bode BW, Lilenquist DR, Brazg RL, Kaiserman KB, Kipnes MS, Thrasher JR, Reed JHC, Slover RH, Philis-Tsimikas A, Christiansen M, Grosman B, Roy A, Vella M, Jonkers RAM, Chen X, Shin J, Cordero TL, Lee SW, Rhinehart AS, Vigersky RA. Safety and Glycemic Outcomes During the MiniMed? Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes. Diabetes Technol Ther. 2022 03; 24(3):178-189.
    View in: PubMed
    Score: 0.011
  36. Gao L, Zhang P, Weng J, Lu J, Guo X, Jia W, Yang W, Zou D, Zhou Z, Pan C, Gao Y, Li X, Zhu D, Wu Y, Garg SK, Ji L. Patient characteristics and 6-month dose of basal insulin associated with HbA1c achievement <7.0% in Chinese people with type 2 diabetes: results from the Observational Registry of Basal Insulin Treatment (ORBIT). J Diabetes. 2020 Sep; 12(9):668-676.
    View in: PubMed
    Score: 0.010
  37. DeSouza C, Cariou B, Garg S, Lausvig N, Navarria A, Fonseca V. Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials. J Clin Endocrinol Metab. 2020 02 01; 105(2).
    View in: PubMed
    Score: 0.009
  38. Danne T, Cariou B, Buse JB, Garg SK, Rosenstock J, Banks P, Kushner JA, McGuire DK, Peters AL, Sawhney S, Strumph P. Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program. Diabetes Care. 2019 05; 42(5):919-930.
    View in: PubMed
    Score: 0.009
  39. Buse JB, Garg SK, Rosenstock J, Bailey TS, Banks P, Bode BW, Danne T, Kushner JA, Lane WS, Lapuerta P, McGuire DK, Peters AL, Reed J, Sawhney S, Strumph P. Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study. Diabetes Care. 2018 Sep; 41(9):1970-1980.
    View in: PubMed
    Score: 0.008
  40. Christiansen MP, Garg SK, Brazg R, Bode BW, Bailey TS, Slover RH, Sullivan A, Huang S, Shin J, Lee SW, Kaufman FR. Accuracy of a Fourth-Generation Subcutaneous Continuous Glucose Sensor. Diabetes Technol Ther. 2017 08; 19(8):446-456.
    View in: PubMed
    Score: 0.008
  41. Buckingham BA, Bailey TS, Christiansen M, Garg S, Weinzimer S, Bode B, Anderson SM, Brazg R, Ly TT, Kaufman FR. Evaluation of a Predictive Low-Glucose Management System In-Clinic. Diabetes Technol Ther. 2017 05; 19(5):288-292.
    View in: PubMed
    Score: 0.008
  42. Sussman M, Sierra JA, Garg S, Bode B, Friedman M, Gill M, Kaufman F, Vigersky R, Menzin J. Economic impact of hypoglycemia among insulin-treated patients with diabetes. J Med Econ. 2016 Nov; 19(11):1099-1106.
    View in: PubMed
    Score: 0.007
  43. Weinstock RS, DuBose SN, Bergenstal RM, Chaytor NS, Peterson C, Olson BA, Munshi MN, Perrin AJ, Miller KM, Beck RW, Liljenquist DR, Aleppo G, Buse JB, Kruger D, Bhargava A, Goland RS, Edelen RC, Pratley RE, Peters AL, Rodriguez H, Ahmann AJ, Lock JP, Garg SK, Rickels MR, Hirsch IB. Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes. Diabetes Care. 2016 Apr; 39(4):603-10.
    View in: PubMed
    Score: 0.007
  44. Sands AT, Zambrowicz BP, Rosenstock J, Lapuerta P, Bode BW, Garg SK, Buse JB, Banks P, Heptulla R, Rendell M, Cefalu WT, Strumph P. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. Diabetes Care. 2015 Jul; 38(7):1181-8.
    View in: PubMed
    Score: 0.007
  45. Klonoff DC, Bergenstal RM, Garg SK, Bode BW, Meredith M, Slover RH, Ahmann A, Welsh JB, Lee SW. ASPIRE In-Home: rationale, design, and methods of a study to evaluate the safety and efficacy of automatic insulin suspension for nocturnal hypoglycemia. J Diabetes Sci Technol. 2013 Jul 01; 7(4):1005-10.
    View in: PubMed
    Score: 0.006
  46. Bergenstal RM, Klonoff DC, Garg SK, Bode BW, Meredith M, Slover RH, Ahmann AJ, Welsh JB, Lee SW, Kaufman FR. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013 Jul 18; 369(3):224-32.
    View in: PubMed
    Score: 0.006
  47. Brazg RL, Bailey TS, Garg S, Buckingham BA, Slover RH, Klonoff DC, Nguyen X, Shin J, Welsh JB, Lee SW. The ASPIRE study: design and methods of an in-clinic crossover trial on the efficacy of automatic insulin pump suspension in exercise-induced hypoglycemia. J Diabetes Sci Technol. 2011 Nov 01; 5(6):1466-71.
    View in: PubMed
    Score: 0.005
  48. Young KA, Snell-Bergeon JK, Naik RG, Hokanson JE, Tarullo D, Gottlieb PA, Garg SK, Rewers M. Vitamin D deficiency and coronary artery calcification in subjects with type 1 diabetes. Diabetes Care. 2011 Feb; 34(2):454-8.
    View in: PubMed
    Score: 0.005
  49. Maahs DM, Snell-Bergeon JK, Kinney GL, Wadwa RP, Garg S, Ogden LG, Rewers M. ACE-I/ARB treatment in type 1 diabetes patients with albuminuria is associated with lower odds of progression of coronary artery calcification. J Diabetes Complications. 2007 Sep-Oct; 21(5):273-9.
    View in: PubMed
    Score: 0.004
  50. Kretowski A, McFann K, Hokanson JE, Maahs D, Kinney G, Snell-Bergeon JK, Wadwa RP, Eckel RH, Ogden L, Garg S, Li J, Cheng S, Erlich HA, Rewers M. Polymorphisms of the renin-angiotensin system genes predict progression of subclinical coronary atherosclerosis. Diabetes. 2007 Mar; 56(3):863-71.
    View in: PubMed
    Score: 0.004
  51. Edelman S, Garg S, Frias J, Maggs D, Wang Y, Zhang B, Strobel S, Lutz K, Kolterman O. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care. 2006 Oct; 29(10):2189-95.
    View in: PubMed
    Score: 0.004
  52. Wadwa RP, Kinney GL, Maahs DM, Snell-Bergeon J, Hokanson JE, Garg SK, Eckel RH, Rewers M. Awareness and treatment of dyslipidemia in young adults with type 1 diabetes. Diabetes Care. 2005 May; 28(5):1051-6.
    View in: PubMed
    Score: 0.003
  53. Maahs DM, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, Hokanson J, Ehrlich J, Garg S, Eckel RH, Rewers MJ. Hypertension prevalence, awareness, treatment, and control in an adult type 1 diabetes population and a comparable general population. Diabetes Care. 2005 Feb; 28(2):301-6.
    View in: PubMed
    Score: 0.003
  54. Dabelea D, Kinney G, Snell-Bergeon JK, Hokanson JE, Eckel RH, Ehrlich J, Garg S, Hamman RF, Rewers M. Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. Diabetes. 2003 Nov; 52(11):2833-9.
    View in: PubMed
    Score: 0.003
  55. Snell-Bergeon JK, Hokanson JE, Jensen L, MacKenzie T, Kinney G, Dabelea D, Eckel RH, Ehrlich J, Garg S, Rewers M. Progression of coronary artery calcification in type 1 diabetes: the importance of glycemic control. Diabetes Care. 2003 Oct; 26(10):2923-8.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)